Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Central Nervous System Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
52 drugs · 206 active trials
5 drugs · 33 active trials
5 drugs · 185 active trials
Outside the funnel: Phase not stated 1 · Withdrawn 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 19 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Venetoclax | Phase 1 | Phase 1 | 1 | 0 | 0 | 2 | 0 | — | — | May 12, 2020 |
| Abexinostat | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Jun 26, 2023 |
| Amivantamab | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Oct 9, 2024 |
| Belzutifan | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Dec 7, 2016 |
| Lonafarnib | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Dec 21, 2004 |
| Lorlatinib | Phase 1 | Early Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Aug 3, 2025 |
| Lutetium (177lu) Vipivotide Tetraxetan | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Oct 27, 2025 |
| Polatuzumab Vedotin | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 17, 2025 |
| Savolitinib | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 27, 2018 |
| Crizotinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Nov 27, 2012 |
| Navtemadlin | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Dec 27, 2012 |
| Alvocidib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2001-04 |
| Bafetinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-12 |
| Bicalutamide | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 8, 2025 |
| Capmatinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 22, 2015 |
| Glofitamab | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 30, 2025 |
| Ixazomib | Phase 1 | Early Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 24, 2016 |
| MTOR Kinase Inhibitor AZD8055 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 4, 2011 |
| Pilaralisib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-01 |
| Prexasertib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 8, 2019 |
| Ridaforolimus | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-07 |
| Rindopepimut | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-06 |
| Tanespimycin | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 1999-10 |
| Tisagenlecleucel | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jan 1, 2019 |
| Vatalanib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2006-09 |
| Vistusertib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 22, 2016 |
| Aumolertinib | Phase not stated | N/A | 0 | 0 | 0 | 1 | 0 | — | — | 2021-07 |
| Cytarabine | Withdrawn | Phase 3 | 4 | 1 | 2 | 9 | 1 | EU | — | 2005-09 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.